ONCOPRO NCCN LUNG CANCER PANEL Test
Test Name: ONCOPRO NCCN LUNG CANCER PANEL Test
Test Components:
- EGFR
- ALK
- ERBB2
- BRAF
- MET
- RET
- ROS1
- NTRK1
- KRAS
- MSI
Price: 23400.0 AED
Sample Condition: 20 mL whole blood in 2 Streck tubes available from LPL. Ship immediately at 18-22°C. DO NOT REFRIGERATE OR FREEZE. Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32) is mandatory.
Report Delivery: Sample Daily by 9 am; Report 35 Working days
Method: Next Generation Sequencing
Test type: Cancer
Doctor: Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information: Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32) is mandatory.
Test Details
The ONCOPRO NCCN Lung Cancer Panel Test is a diagnostic test that analyzes a patient’s tumor tissue for specific genetic mutations and biomarkers associated with lung cancer. The test is based on the guidelines provided by the National Comprehensive Cancer Network (NCCN) and identifies mutations in genes such as EGFR, ALK, ROS1, BRAF, MET, RET, and NTRK. These mutations are important in predicting response to targeted therapies and can help guide treatment decisions.
The ONCOPRO NCCN Lung Cancer Panel Test is a non-invasive test that can be performed on a small tissue sample obtained through a biopsy or surgery. The results of the test are used by physicians to develop personalized treatment plans for patients with lung cancer.
Test Name | ONCOPRO NCCN LUNG CANCER PANEL Test |
---|---|
Components | *EGFR *ALK *ERBB2 *BRAF *MET *RET *ROS1 *NTRK1 *KRAS*MSI |
Price | 23400.0 AED |
Sample Condition | 20 mLwhole bloodin 2 Streck tubes available from LPL. Ship immediately at 18\u0192??22?\u00f8C. DO NOT REFRIGERATE OR FREEZE. Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32)is mandatory. |
Report Delivery | Sample Daily by 9 am; Report 35 Working days |
Method | Next Generation Sequencing |
Test type | Cancer |
Doctor | Oncologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32)is mandatory. |
Test Details | The ONCOPRO NCCN Lung Cancer Panel Test is a diagnostic test that analyzes a patient’s tumor tissue for specific genetic mutations and biomarkers associated with lung cancer. The test is based on the guidelines provided by the National Comprehensive Cancer Network (NCCN) and identifies mutations in genes such as EGFR, ALK, ROS1, BRAF, MET, RET, and NTRK. These mutations are important in predicting response to targeted therapies and can help guide treatment decisions. The ONCOPRO NCCN Lung Cancer Panel Test is a non-invasive test that can be performed on a small tissue sample obtained through a biopsy or surgery. The results of the test are used by physicians to develop personalized treatment plans for patients with lung cancer. |